Key result
Sacubitril/valsartan linked to ~84% lower adverse-effect discontinuation vs thiazide diuretics.
Why the study?
The hypertension paradox is an urgent clinical issue in Japan where thiazide diuretics are underused despite widespread use of ARBs and CCBs, and the efficacy and safety differences between sacubitril valsartan and thiazide diuretics in poorly controlled hypertension are unclear.
Does sacubitril-valsartan improve blood pressure control and safety compared to thiazide diuretics in patients with uncontrolled hypertension on RAS inhibitors and CCBs?
Observational (n=648)
Does sacubitril-valsartan improve blood pressure control and safety compared to thiazide diuretics in patients with uncontrolled hypertension on RAS inhibitors and CCBs?
In patients with uncontrolled hypertension, switching to sacubitril-valsartan provides similar blood pressure reduction to adding a thiazide diuretic, but with better tolerability and favorable metabolic and renal effects.
Answers are grounded in this paper and cite their sources.
May improve adherence in uncontrolled hypertension; leaves open need for RCTs to confirm BP efficacy versus thiazides.
Background: The hypertension paradox is an urgent issue in clinical practice. Although ARBs and calcium channel blockers (CCBs) were widely used, less than 10% of patients used thiazide diuretics in Japan. Sacubitril valsartan can be used for not only patients with heart failure but also with hypertension. This study aimed to evaluate the differences of an efficacy and safety between sacubitril valsartan and thiazide diuretics in patients with poorly BP control. Methods: Patients who showed ≥130/80 mmHg in the office despite a combination treatment of RAS inhibitors and CCBs were included. The comparison between patients treated with the addition of thiazide diuretics (THZ group, n=267) and those transferred from RAS inhibitors to sacubitril valsartan (SacVal group, n=381) was analyzed. A general linear mixed model (GLMM) was used for the analysis of clinical findings at baseline, 4 months, and 12 months. The rate of discontinuation was analyzed using the Cox proportional hazard model. Results: The baseline backgrounds of the THZ /SacVal group were as follows; female 39/35 (%), mean age, body weight (BW), and eGFR at baseline were 67.8 ± 13.1/72.3±12.6 (years) (p<0.001), 68.1±15.7/66.2±14.2(kg), 61.2±20.9/56.8±20.3 (ml/min/1.73 m2) (p=0.01), respectively. In the GLMM analysis, significant decrease in office and home BP after treatment was observed in both groups (p<0.001), however, no significant interaction effects between the type of drug and time course were observed for BP. Significant interaction effects were observed for eGFR, uric acid (UA), logarithmic value of ACR (LnACR), BW, and hemoglobin A1c (HbA1c) (all p<0.001). eGFR, UA, and LnACR were significantly decreased (p<0.001), increased (p<0.001), and decreased (p<0.001), respectively, in the THZ group during the time course. Significant decreases were observed in BW and HbA1c in the SacVal group (p<0.001). Treatment discontinuation due to adverse effects was significantly more frequent in 34 cases (13%) in the THZ group, than 12 cases (3%) in the SacVal group with hazard ratio of 6.3 [95% CI, 2.7, 14.9] (p<0.001). Conclusion: Both treatments decreased BP; however, compared to thiazide, sacubitril valsartan resulted in a superior reduction in BW, HbA1c, and favorable changes in kidney function, with better treatment adherence.
No takes yet. Share an insight, caveat, or question.
Kobayashi et al. (2024) conducted an observational in Uncontrolled Hypertension (n=648). Sacubitril valsartan vs. Thiazide diuretics was evaluated on Treatment discontinuation due to adverse effects (HR 6.3, 95% CI 2.7-14.9, p=<0.001). Sacubitril valsartan was associated with lower treatment discontinuation due to adverse effects compared to thiazide diuretics.
Synapse has enriched 10 related papers. Consider them for comparative context: